Mirum Pharmaceuticals CFO Sells $526,960 Worth of Stock Amid Q2 Growth and Raised Price Targets

Mirum Pharmaceuticals CFO Eric Bjerkholt sold 8,000 shares worth $526,960. The company reported a 64% increase in revenue to $128 million in Q2, leading to a full-year revenue guidance of $490-$510 million. Analysts have raised price targets due to strong sales growth and the successful launch of Livmarli. Despite high operating expenses and international sales variability, Mirum's outlook remains optimistic, supported by its financial position and strategic initiatives.

Mirum Pharmaceuticals Inc. reported robust financial results for the second quarter of 2025, highlighting a 64% increase in revenue to $128 million. The company's earnings per share (EPS) came in at -$0.12, significantly outperforming the forecasted -$0.33. The revenue growth was driven by the successful launch of LIVMARLI, a drug treating Alagille syndrome and PFIC.

Following the earnings announcement, Mirum's stock price increased by 2.99% in aftermarket trading, closing at $53.39. The company's market capitalization stands at $2.64 billion, with the stock trading near its 52-week high of $54.78. Mirum's CEO, Chris Pete, noted that 2025 is shaping up to be another outstanding year for the company, with strong momentum behind both its commercial medicines and pipeline.

Key Takeaways:
- Revenue: $128 million, a 64% increase year-over-year
- EPS: -$0.12, compared to the forecasted -$0.33
- Full-year revenue guidance raised to $490 million to $510 million

Mirum's financial performance was bolstered by the successful launch of LIVMARLI, which is continuing to bring substantial benefit to patients and build a differentiated position with physicians. The company's strong performance across its medicines led to an increase in full-year revenue guidance.

The company's CFO, Eric Bjerkholt, sold 8,000 shares worth $526,960. Despite high operating expenses and international sales variability, Mirum's outlook remains optimistic, supported by its financial position and strategic initiatives.

Analysts have raised price targets due to the strong sales growth and the successful launch of LIVMARLI. The company's pipeline includes several promising studies, with the VISTA PSC study on track to complete enrollment this quarter and top-line data expected in the second quarter of 2026.

Mirum Pharmaceuticals' robust performance in Q2 2025, coupled with its optimistic outlook, positions the company for continued growth in the rare disease market. [1]

References:
[1] https://www.investing.com/news/transcripts/earnings-call-transcript-mirum-pharmaceuticals-sees-revenue-boost-in-q2-2025-93CH-4175140